Enliven Therapeutics, Inc (ELVN) Tops Q4 EPS by 6c

Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q4 EPS of ($0.46), $0.06 better than the analyst estimate of ($0.52).

For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.

You May Also Be Interested In

• Raymond James Reiterates Outperform Rating on Southwest (LUV)
• Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance
• Victoria Secret (VSXY) PT Lowered to $95 at BofA Securities